The preclinical rationale for the use of insulin-like growth factor-I in amyotrophic lateral sclerosis

Drugs of Today

Volumn 34, Issue 1, 1998, Pages 65-77

  Festoff, Barry W ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CELL SURFACE RECEPTOR; CILIARY NEUROTROPHIC FACTOR; PROTEIN TYROSINE KINASE; PROTEINASE; RECOMBINANT SOMATOMEDIN C; RILUZOLE; SERINE PROTEINASE; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; THROMBIN;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DRUG MECHANISM; HUMAN; META ANALYSIS; MOTONEURON; MUSCLE CELL; NERVE FIBER; NEUROMUSCULAR SYNAPSE; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; REVIEW; SIGNAL TRANSDUCTION;

EID: 0031931736     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1998.34.1.485201     Document Type: Review

References (78)

1. Zapf, J., Froesch, E.R. Insulin-like growth factor/somatomedins: Structure, secretion, biological actions and physiological role. Horm Res 1986, 24: 121-30.
2. De Meyts, P., Christoffersen, C.T., Urso, B. et al. Role of the time factor in signaling specificity: Application to mitogenic and metabolic signaling by the insulin and insulin-like growth factor-I receptor tyrosine kinases. Metabolism 1995, 44: 2-11.
3. Adamo, M., Roberts, C. Jr., LeRoith, D. How distinct are the insulin and insulin-like growth factor I signalling systems? Biofactors 1992, 3: 151-7.
4. Scrimgeour, A.G., Blakesley, V.A., Stannard, B.S. et al. Mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways are not sufficient for insulin-like growth factor I-induced mitogenesis and tumorigenesis. Endocrinology 1997, 138: 2552-8.
5. Coolican, S.A., Samuel, D.S., Ewton, D.Z. et al. The mitogenic and myogenic actions of insulin- like growth factors utilize distinct signaling pathways. J Biol Chem 1997, 272: 6653-62.
6. Kim, B., Leventhal, P.S., Saltiel, A.R. et al. Insulin-like growth factor-I-mediated neunte outgrowth in vitro requires mitogen-activated protein kinase activation. J Biol Chem 1997, 272: 21268-73.
7. Milasincic, D.U., Calera, M.R., Farmer, S.R. et al. Stimulation of C2C12 myoblast growth by basic fibroblast growth factor and insulin-like growth factor I can occur via mitogen-activated protein kinase-dependent and -independent pathways. Mol Cell Biol 1996, 16: 5964-73.
8. Alessi, D.R., Andjelkovic, M., Caudwell, B. et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 1996, 15: 6541-51.
9. Alessi, D.R., James, S.R., Dowries, C.P. et al. Characterization of a 3-phosphoinositide- dependentprotein kinase which phosphorylates and activates protein kinase B alpha. Curr Biol 1997,7:261-9.
10. Kulik, G., Klippel, A., Weber, M.J. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt Mol Cell Biol 1997, 17: 1595-606.
11. Franke, T.F., Kaplan, D.R., Cantley, L.C. P13K: Downstream AKTion blocks apoptosis. Cell 1997, 88: 435-7.
12. Roth, R.A., Stover, C., Hari, J. et al. Interactions of the receptor for insulin-like growth factor II with mannose-6-phosphate and antibodies to the mannose-6-phosphate receptor. Biochem Biophys Res Commun 1987, 149: 600-6.
13. Hintz, R.L., Liu, F. Demonstration of specific plasma protein sites for somatomedin. J Clin Endocrinol Metab 1977, 45: 988-95.
14. Shimasaki, S., Ling, N. Identification and molecular characterization of insulin-like growth factor binding protein (IGF-1, -2, -3, -4, -5, and -6). Prog Growth Factor Res 1991, 3: 243-66.
15. Clemmons, D.R. Insulin-like growth factor binding proteins and their rote in controlling IGF actions. Cytokine Growth Factor Rev 1997, 8: 45-62.
16. Albiston, A.L., Herington, A.C. Cloning and characterization of the growth hormone-dependent insulin-like growth factor binding protein (IGFBP-3) in the rat. Biochem Biophys Res Commun 1990, 166: 892-7.
17. Gargosky, S.E., Tapanainen, P., Rosenfeld, R.G. Administration of growth hormone (GH), but not insulin-like growth factor-I (IGF-I), by continuous infusion can induce the formation of the 150-kilodalton IGF-binding protein-3 complex in GH-deficient rats. Endocrinology 1994, 134: 2267-76.
18. Lemmey, A.B., Glassford, J., Flick Smith, H.C. et al. Differential regulation of tissue insulin-like growth factor-binding protein (IGFBP)-3, IGF-I and IGF type 1 receptor mRNA levels, and serum IGF-I and IGFBP concentrations by growth hormone and IGF-I. J Endocrinol 1997, 154: 319-28.
19. Hosseniopp, P., Segovia, B., Lassarre, C. et al. Evidence of enzymatic degradation of insulin- like growth factor-binding proteins in the 150K complex during pregnancy. J Clin Endocrinol Metab 1990, 71: 797-805.
20. Lamson, G., Gmdice, L.C., Rosenfeld, R.G. A simple assay for proteolysis of IGFBP-3. J Clin Endocrinol Metab 1991, 72: 1391-3.
21. Rajah, R., Katz, L., Nunn, S. et al. Insulin-like growth factor binding protein (IGFBP) proteases: Functional regulators of cell growth. Prog Growth Factor Res 1995, 6: 273-84.
22. Nam, T.J., Busby, W.H. Jr., Clemmons, D.R. Human fibroblasts secrete a serine protease that cleaves insulin-like growth factor-binding protein-5. Endocrinology 1994, 135: 1385-91.
23. Chernausek, S.D., Smith, C.E., Duffin, K.L. et al. Proteolytic cleavage of insulin-like growth factor binding protein 4 (IGFBP-4). Localization of cleavage site to non-homologous region of native IGFBP-4. J Biol Chem 1995, 270: 11377-82.
24. Parker, A., Gockerman, A., Busby, W.H. et al. Properties of an insulin-like growth factor-binding protein-4 protease that is secreted by smooth muscle cells. Endocrinology 1995, 136: 2470-6.
25. Fielder, P.J., Rosenfeld, R.G., Graves, H.C. et al. Biochemical analysis of prostate specific antigen-proteolyzed insulin-like growth factor binding protein-3. Growth Regul 1994, 4: 164-72.
26. Cohen, P., Peehl, D.M., Graves, H.C. et al. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol 1994, 142: 407-15.
27. Cohen, P., Peehl, D.M., Baker, B. et al. Insulin- like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia. J Clin Endocrinol Metab 1994, 79: 1410-5.
28. LeRoith, D., Werner, H., Faria, T.N. et al. Insulin- like growth factor receptors: Implications for nervous system function. Ann NY Acad Sci 1993, 692: 22-32.
29. Sara, V.R., Hall, K, Insulin-like growth factors and their binding proteins. Physiol Rev 1990, 70: 591-614.
30. Sara, V.R., Carlsson-Skwirut, C., Drakenberg, K. et al. The biological role of truncated insulin- like growth factor-1 and the tripeptide GPE in the central nervous system. Ann NY Acad Sci 1993, 692: 183-91.
31. Simes, J.M., Wallace, J.C., Walton, P.E. The effects of insulin-like growth factor-I (IGF-I), IGF-II and des(1-3)IGF-I, a potent IGF analogue, on growth hormone and IGF-binding protein secretion from cultured rat anterior pituitary cells. J Endocrinol 1991, 130: 93-9.
32. Lord, A.P.D., Bastian, S.E.P., Read, L.C. et al. Differences in the association of insulin-like growth factor-I (IGF-I) and IGF-I variants with rat, sheep, pig, human and chicken plasma- binding proteins. J Endocrinol 1994, 140: 475-82.
33. Hansson, H.A., Rozell, B., Skottner, A. Rapid axoplasmic transport of insulin-like growth factor I in the sciatic nerve of adult rat. Cell Tissue Res 1987, 247: 241-7.
34. Doré, S., Kar, S., Quirion, R. Rediscovering an old friend, IGF-I: Potential use in the treatment of neurodegenerative diseases. Trends Neurosci 1997, 20: 326-31.
35. Cheng, B., Mattson, M.P. IGF-I and IGF-II protect cultured hippocampal and septal neurons against calcium-mediated hypoglycemic damage. J Neurosci 1992, 12: 1558-66.
36. Doré, S., Kar, S., Quirion, R. Insulin-like growth factor I protects and rescues hippocampal neurons against β-amyloid- and human amylin- induced toxicity. Proc Natl Acad Sci USA 1997, 94: 4772-7.
37. Neff, N.T., Prevette, D., Houenou, L.J. et al. Insulin-like growth factors: Putative muscle- derived trophic agents that promote motoneuron survival. J Neurobiol 1993, 24: 1578-88.
38. Caroni, P., Grandes, P. Nerve sprouting in innervated adult skeletal muscle induced by exposure to elevated levels of insulin-like growth factors. J Cell Biol 1990, 110: 1307-17.
39. Caroni, P., Schneider, C., Kiefer, M.C. et al. Role of muscle insulin-like growth factors in nerve sprouting: Suppression of terminal sprouting in paralyzed muscle by IGF-binding protein 4. J Cell Biol 1994 125: 893-902.
40. Caroni, P., Schneider, C. Signaling by insulin- like growth factors in paralyzed skeletal muscle: Rapid induction of IGF1 expression in muscle fibers and prevention of interstitial cell proliferation by IGF-BP5 and IGF-BP4, J Neurosci 1994, 14: 3378-88.
41. Moss, A.M., Livingston, J.N. Distinct β-subunits are present in hybrid insulin-like-growth-factor-1 receptors in the central nervous system. Biochem J 1993, 294: 685-92.
42. De Meyts, P., Wallach, B., Christoffersen, C.T. et al. The insulin-like growth factor-I receptor. Structure, ligand-binding mechanism and signal transduction. Horm Res 1994, 42: 152-69.
43. LeRoith, D., Werner, H., Beitner Johnson, D. et al. Molecular and cellular aspects of the insulin- like growth factor I receptor. Endocrinol Rev 1995, 16: 143-63.
44. Brass, B.J., Nonner, D., Barrett, J.N. Differential effects of insulin on choline acetyltransferase and glutamic acid decarboxylase activities in neuron-rich striatal cultures. J Neurochem 1992, 59: 415-24.
45. Bondy, C., Werner, H., Roberts, C.T. Jr. et al. Cellular pattern of type-1 insulin-like growth factor receptor gene expression during maturation of the rat brain: Comparison with insulin-like growth factors I and II. Neuroscience 1992, 46: 909-23.
46. D'Mello, S.R., Borodezt, K., Soltoff, S.P Insulin- like growth factor and potassium depolarization maintain neuronal survival by distinct pathways: Possible involvement of P13-kinase in IGF-I signaling. J Neurosci 1997, 17: 1548-60.
47. Dudek, H., Datta, S.R., Franke, TR et al. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 1997, 275: 661-5.
48. Singleton, J.R., Dixit, V.M., Feldman, E.L. Type 1 insulin like growth factor receptor activation regulates apoptotic proteins. J Biol Chem 1996, 271: 31791-4.
49. Ocrant, I., Fay, C.T., Parmelee, J.T. Characterization of insulin-like growth factor binding proteins produced in the rat central nervous system. Endocrinology 1990, 127: 1260-7.
50. Lee, W.H., Javedan, S., Bondy, C.A. Coordinate expression of insulin-like growth factor system components by neurons and neuroglia during retinal and cerebetlar development. J Neurosci 1992, 12: 4737-44.
51. Logan, A., Gonzalez, A.M., Hill, D.J. et al. Coordinated pattern of expression and localization of insulin-like growth factor-II (IGF-II) and IGF- binding protein-2 in the adult rat brain. Endocrinology 1994, 135: 2255-64.
52. Sullivan, K.A., Feldman, E.L. Immunohistochemical localization of insulin-like growth factor-II (IGF-II) and IGF-binding protein-2 during development in the rat brain. Endocrinology 1994, 135: 540-7.
53. Ma, J., Yang, S.X., Ho, G.J. et al. Insulin-like growth factor binding protein-1 at mouse neuromuscular synapses. Synapse 1994, 17: 225-9.
54. Ma, J., Yang, S.X., Ho, G.J. et al. Insulin-like growth factor binding protein-1 is pre-synaptic at mouse neuromuscular synapses and is transported in nerve. Neurochem Res 1994, 19: 1363-8.
55. Müller, H.L., Oh, Y., Gargosky, S.E. et al. Concentrations of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3), IGF, and IGFBP-3 protease activity in cerebrospinal fluid of children with leukemia, central nervous system tumor, or meningitis. J Clin Endocrinol Metab 1993, 77: 1113-9.
56. Rajah, R., Bhala, A., Nunn, S.E. et al. 7S nerve growth factor is an insulin-like growth factor- binding protein protease. Endocrinology 1996, 137: 2676-82.
57. Matsumoto, T., Gargosky, S.E., Kelley, K. et al. Characterization of an insulin-like growth factor binding protein-5 protease produced by rat articular chondrocytes and a neuroblastoma cell line. Growth Regul 1996, 6: 185-90.
58. Braunstein, G.D., Reviczky, A.L. Serum insulin- like growth factor-I levels in amyotrophic lateral sclerosis. J Neural Neurosurg Psychiatry 1987, 50: 792-4.
59. Smith, R.A., Melmed, S., Sherman, B. et al. Recombinant growth hormone treatment of amyotrophic lateral sclerosis. Muscle Nerve 1993, 16: 624-33.
60. Brooks, B.R. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" Workshop contributors. J Neurol Sci 1994, 124 (Suppl.): 96-107.
61. Torres-Aleman, I., Barrios, V., Berciano, J. The peripheral insulin-like growth factor system in amyotrophic lateral sclerosis and multiple sclerosis. Neurology 1998, 50: in press.
62. Adem, A., Ekblom, J., Gillberg, P.G. et al. Insulin-like growth factor-1 receptors in human spinal cord: Changes in amyotrophic lateral sclerosis. J Neural Transm Gen Sect 1994, 97: 73-84.
63. Adem, A., Ekblom, J., Gillberg, P.G. Growth factor receptors in amyotrophic lateral sclerosis. Mol Neurobiol 1994, 9: 225-31.
64. Doré, S., Krieger, C., Kar, S. et al. Distribution and levels of insulin-like growth factor (IGF-I and IGF-II) and insulin receptor binding sites in the spinal cords of amyotrophic lateral sclerosis (ALS) patients. Brain Res Mol Brain Res 1996, 41: 128-33.
65. Whitehouse, P.J., Wamsley, J.K., Zarbin, M.A. et al. Neurotransmitter receptors in amyotrophic lateral sclerosis: Possible relationship to sparing of eye movements (letter). Ann Neurol 1985, 17: 518.
66. Festoff, B.W., Yang, S.X., Vaught, J. et al. The insulin-like growth factor signaling system and ALS neurotrophic factor treatment strategies. J Neurol Sci 1995, 129: 114-21.
67. Festoff, B.W., Yang, S.X., Stong, D. Strategies for the use of recombinant human growth hormone and insulin-like growth factor I in amyotrophic lateral sclerosis. In: GHRH, GH, and IGF-I Basic and Clinical Advances. Blackman, M.R., Harman, S.M., Roth, J., Shapiro, J.R. (Eds.). Springer-Verlag: New York 1995, 110-28.
68. Festoff, B.W. Neuromuscular junction macromolecules in the pathogenesis of amyotrophic leteral sclerosis. Med Hypotheses 1980, 6: 121-31.
69. Antel, J.P., Chelmicka Schoff, E., Sportiello, M. et al. Muscle acid protease activity in amyotrophic lateral sclerosis: Correlation with clinical and pathologic features. Neurology 1982, 32: 901-3.
70. Shaw, P.J., Ince, P.G., Falkous, G. et al. Cytoplasmic, lysosomal and matrix protease activities in spinal cord tissue from amyotrophic lateral sclerosis (ALS) and control patients. J Neurol Sci 1996, 139: 71-5.
71. Lange, D.J., Felice, K.J., Festoff, B.W. et al. Recombinant human insulin-like growth factor-I in ALS: Description of a double-blind, placebo- controlled study. North American ALS/IGF-I Study Group. Neurology 1996, 47: S93-4.
72. Lai, B.C., Felice, K.J., Festoff, B.W. et al. Effect of human recombinant insulin-like growth factor I on progression of ALS. Neurology 1997, 49: 1621-30.
73. Bensimon, G., Lacombiez, L., Meininger, V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. New Engl J Med 1994, 330: 585-91.
74. Lacombiez, L., Bensimon, G., Leigh, P.N. et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/ Riluzole Study Group II. Lancet 1996, 347: 1425-31.
75. Lacomblez, L., Bensimon, G., Leigh, P.N. et al. A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-II. Neurology 1996, 47: 3242-50.
76. Smirnova, I.V., Zhang, S.X., Citron, B.A. et al. Thrombin is an extracellular signal that activates intracellular death protease pathways inducing apoptosis in model motor neurons. J Neurobiol 1998, in press.
77. Donovan, F.M., Pike, C.J., Cotman, C.W. et al. Thrombin induces apoptosis in cultured neurons and astrocytes via a pathway requiring tyrosine kinase and RhoA activities. J Neurosci 1997, 17: 5316-26.
78. Mattson, M.P., Furukawa, K. Programmed cell life: Anti apoptotic signaling and therapeutic strategies for neurodegenerative disorders. Restor Neurol Neurosci 1996, 9: 191-205.